January 29, 2026 
3 min read 
Bayer is a German company that reports financials in euros and operates major agriculture and pharmaceutical divisions. The company is the largest seed and pesticide provider in the U.S. and maintains a pipeline of new drug launches.
The company has faced thousands of claims alleging that a weed-killer causes cancer and failed to warn consumers. The U.S. Supreme Court has agreed to review the litigation. A prior example cited in public commentary referenced a DOJ case dismissal that followed a change in U.S. presidential administration.
- Established presence in life-science research across agriculture and pharmaceuticals with ongoing product development.
- An active drug pipeline with new products approaching market entry.
- Leading position in seeds and pesticides in the U.S. links performance to U.S. farm conditions and cyclical agricultural demand.
- Currency exposure: reporting in euros means a weaker U.S. dollar can reduce reported revenue when converting U.S. dollar sales into euros while also potentially encouraging U.S. crop exports.
- U.S. health policy changes include most-favored-nation pricing demands that have been described as capable of reducing profit margins for some drugs. Public commentary noted that U.S. pricing had been multiple times higher than European prices for some products and that some drugs may be excluded from initial policy scope.
The stock experienced a post-earnings rally that began in November and advanced rapidly, with shares rising substantially over a two-month span. Recent momentum has been driven by the combination of the Supreme Court decision to review the litigation and the company’s reported results.
Near-term technicals show resistance formed this week that is now in focus for any continuation. On the longer horizon management has stated the agriculture segment will return to profitability by 2029 and the company has cited an outlook tied to execution of its turnaround and new drug introductions. The company has an earnings report scheduled on February 26.
This material is provided for informational and educational purposes only and does not constitute financial advice. All investments carry risk, including the potential loss of capital.
